Infliximab: Getting the most for your money

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 10, 2007, Pages 1559-1561

  Irving, Peter M ^a   Gibson, Peter R ^a  

^a BOX HILL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALPROTECTIN; CYCLOSPORIN; INFLIXIMAB; LACTOFERRIN; MERCAPTOPURINE; METHOTREXATE; STEROID;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TUBERCULOSIS; ULCERATIVE COLITIS;

EID: 34548544331     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.05003.x     Document Type: Editorial

References (22)

1. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst. Rev. 2000 (2 CD000545.
2. Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N. Engl. J. Med. 1995 332 : 292 7.
3. Feagan BG, Fedorak RN, Irvine EJ et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N. Engl. J. Med. 2000 342 : 1627 32.
4. Quinn MA, Conaghan PG, O'Connor PJ et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005 52 : 27 35.
5. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 2001 345 : 1098 104.
6. Colombel JF, Loftus EV Tremaine WJ et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004 126 : 19 31.
7. Simren M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Bjornsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am. J. Gastroenterol. 2002 97 : 389 96.
8. Barratt HS, Kalantzis C, Polymeros D, Forbes A. Functional symptoms in inflammatory bowel disease and their potential influence in misclassification of clinical status. Aliment. Pharmacol. Ther. 2005 21 : 141 7.
9. Hommes DW, Mikhajlova TL, Stoinov S et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006 55 : 1131 7.
10. Gearry RB. Faecal testing in inflammatory bowel disease. In : Fraser A, Gibson PR, Hibi T, Qian J-M, Scholmerich J, eds. Falk Symposium 151. Emerging Issues in Inflammatory Bowel Disease. Dordrecht : Springer, 2007 135 48.
11. Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Rutgeerts P, Vermeire S. Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm. Bowel Dis. 2007 13 : 372 379.
12. Cottone M, Rosselli M, Orlando A et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994 106 : 643 8.
13. Chaudhary R, Ghosh S. Prediction of response to infliximab in Crohn's disease. Dig. Liver Dis. 2005 37 : 559 63.
14. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 1997 337 : 1029 35.
15. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 359 : 1541 9.
16. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 1999 340 : 1398 405.
17. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 2004 350 : 876 85.
18. Nathan DH, Iser JH, Gibson PR. A single centre experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J. Gastroenterol. Hepatol. (OnlineEarly Articles). doi: 10.1111/j.1440-1746.2007.05006.x
19. Gearry RB, Barclay ML, Roberts RL et al. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern. Med. J. 2005 35 : 580 5.
20. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2005 353 : 2462 76.
21. Jarnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005 128 : 1805 11.
22. Arts J, D'Haens G, Zeegers M et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm. Bowel Dis. 2004 10 : 73 8.